If you are not happy with the results below please do another search
Authoritative Information on Cell and Gene Therapy Markets Cell Therapy And Gene Therapy Markets, 2021-2031 from Kalorama Information presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular – Blood, […]
Cell and Gene Therapy Funding Reached $70 Billion in 2021. How Can You Keep Up with the Activity in this Industry? A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. There are now many approved therapies with proven track records. As the tools have lowered the barriers […]
How Do You Plan to Keep Up With Developments in The Business of Cell and Gene Therapy in 2022? Consider Cell and Gene Therapy Business Outlook Each week brings news in Cell and Gene Therapy, from advances in clinical trials to product launches, from tools development to mergers and acquisitions. It can be a daunting […]
Learn about these 5 key trends based on research featured in Cell Therapy and Gene Therapy Markets, 2021-2031 (published Feb. 2022), a recent report by Kalorama Information Cell and gene therapy products are transforming the treatment of many acquired diseases such as cancer, diabetes, Parkinson’s disease and genetic diseases to correct defective genetic material. Additionally, […]
There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. The US Patent and Trademark Office has ruled against a patent challenge by the University of California, Berkeley (UC Berkeley) over patents awarded to the Broad Institute of MIT and […]
“Oncology, cardiovascular-blood and genetic conditions will be key contributors to the cell and gene therapy market’s strong performance through 2031.” – Kalorama Information It is an exciting and interesting time for companies involved in cell and gene therapy as the industry is forecast to grow tenfold between 2021 to 2031, according to leading medical […]
Total funding from all sources for cell and gene therapy companies totaled $70.8 billion last year, according to a compilation of deals performed by Kalorama Information as part of its recent report. The growth in money being injected into cell and gene therapy companies continues to grow in 2022, according to the firm’s report: Cell […]
There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Intellia Therapeutics, based in Cambridge, MA, has acquired Berkeley, CA-based Rewrite Therapeutics, a private biotech company specializing in developing novel genome editing technologies. Rewrite’s Rewriter platform utilizes CRISPR-guided DNA polymerases […]
There have been a number of recent developments in cell and gene therapy, as detailed in our bi monthly newsletter, Cell and Gene Therapy Business Outlook. New approvals in various countries, and technology licenses. Bristol-Myers Squibb K.K., a Tokyo-based subsidiary of Bristol-Myers Squibb (BMS), has announced that Japan’s Ministry of Health, Labour and Welfare has […]
The following are a dozen developments in the cell and gene therapy market from Volume 1, Issue 14 of Cell and Gene Therapy Business Outlook, published January 10, 2022. Allogene Therapeutics, based South San Francisco, CA, has announced that the Food and Drug Administration has cleared the company to resume clinical trials its CAR-T […]
Email Us: Customer Service
Phone (US): 703-778-3080
Fax: 703-778-3081
